Revelation Biosciences, Inc. (REVBW) Stock Price & Analysis
Revelation Biosciences, Inc. (REVBW) rose 1.01% to USD 0.01 as of July 26, 2026 at 08:35 UTC, according to Nexqual real-time market data.
REVBW last closed at USD 0.01; the session ranged USD 0.01–0.01 on volume of 141 shares. Market capitalization is —, with a 52-week range of USD 0.01–0.01 (NCM). Source: Nexqual, July 26, 2026 at 08:35 UTC.
Key Statistics (as of July 26, 2026 at 08:35 UTC)
| Price | USD 0.01 |
|---|---|
| Change | ▲ 1.01% (up) |
| Previous Close | USD 0.01 |
| Open | USD 0.01 |
| Day Range | USD 0.01 – 0.01 |
| 52-Week Range | USD 0.01 – 0.01 |
| Volume | 141 shares |
| Market Cap | — |
| Exchange | NCM |
Analyst Ratings (REVBW)
Wall Street analysts rate REVBW "None", per Nexqual as of July 26, 2026 at 08:35 UTC.
| Consensus Rating | None |
|---|
Earnings (REVBW)
| Revenue Estimate | $0 |
|---|
Source: Nexqual, July 26, 2026 at 08:35 UTC.
Financials & Fundamentals (REVBW)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -124.41% |
| Debt / Equity | 5.84 |
| Current Ratio | 10.02 |
| Total Cash | $14.11M |
| Total Debt | $759,044 |
| Free Cash Flow | $-5.16M |
Source: Nexqual, July 26, 2026 at 08:35 UTC.
Financial Health Score (REVBW)
Nexqual rates Revelation Biosciences, Inc.'s overall financial health "Mixed" across five dimensions, as of July 26, 2026 at 08:35 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $14M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$9M |
| Efficiency | Critical — ROE -124%, ROA -66.2% |
Ownership (REVBW)
| Float | 3.44M |
|---|
Source: Nexqual, July 26, 2026 at 08:35 UTC.
Leadership (REVBW)
Revelation Biosciences, Inc. is led by James M. Rolke (age 56), Chairman & CEO, per Nexqual as of July 26, 2026 at 08:35 UTC.
| Chairman & CEO | James M. Rolke (age 56) |
|---|---|
| CFO & Corporate Secretary | Chester Stanley Zygmont (age 45) |
| Vice President of Human Resources & Investor Relations | Sandra Vedrick |
| Senior Director of Clinical Projects | Carol Odle |
Major Backers & Investors (REVBW)
Notable institutional backers of Revelation Biosciences, Inc. include Linden Advisors LP, Clear Street Group Inc., Pine Valley Investments Ltd Liability Co., according to Nexqual as of July 26, 2026 at 08:35 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Linden Advisors LP | 10.46% |
| Clear Street Group Inc. | 7.66% |
| Pine Valley Investments Ltd Liability Co. | 7.59% |
| T3 Companies, LLC | 6.13% |
| Toronto Dominion Bank | 3.08% |
| Wolverine Asset Management, LLC | 1.69% |
| Jane Street Group, LLC | 1.55% |
| Soltis Investment Advisors LLC | 1.47% |
Source: Nexqual, July 26, 2026 at 08:35 UTC.
From Revelation Biosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- We also rely on trade secret protection of our confidential information and know-how relating to our proprietary technology, platforms, and Product Candidates.   18   As of February 23, 2026, our patent portfolio includes one patent family directed to MPLA formulations, including Gemini.
- Potential Future Applications for Gemini The Gemini Platform Our current therapeutic programs are based on our proprietary Gemini formulation of PHAD ® , a synthetic version of monophosphoryl lipid A ("MPLA") with a well-established biology.
- The CDC says Medicare in 2015 alone had an annual expenditure of over $10 billion and growing for AKI, with spending for AKI related costs of approximately $42,077 per patient.
- For Product Candidates regulated under the FD&C Act, FDA must approve a New Drug Application ("NDA").
Partnerships
- Revelation met with FDA at the end of 2025 and obtained agreement on a single Phase 2/3 adaptive design study with a primary composite endpoint of death and/or dialysis for submission of a new drug application (NDA).
- P-values generated using two-tailed t-test with alpha at 5%.   16   Development Plans AKI Revelation met with FDA at the end of 2025 and obtained agreement on a single Phase 2/3 adaptive design study comprising approximately 300 patients with AKI and a primary composite endpoint of death and/or need for dialysis, the data from which can be used for submission of a new drug application (NDA).
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| REVB | Revelation Biosciences, Inc. | USD 1.06 | ▼ 7.83% |
| SABSW | SAB Biotherapeutics, Inc. | USD 0.01 | ▲ 34.23% |
| KTTAW | Pasithea Therapeutics Corp. Warrant | USD 0.01 | ▲ 0% |
| CDIOW | Cardio Diagnostics Holdings, Inc. | USD 0.02 | ▲ 25% |
| ICUCW | SeaStar Medical Holding Corporation | USD 0.02 | ▲ 28.8% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 08:35 UTC. This page is informational and not investment advice.